1. Modern opportunities for the diagnosis and treatment of vulvovaginal candidiasis (in aid of a practitioner)
- Author
-
E. R. Dovletkhanova and P. R. Abakarova
- Subjects
0301 basic medicine ,medicine.medical_specialty ,030106 microbiology ,medicine.disease_cause ,Adult women ,03 medical and health sciences ,Sexually active ,0302 clinical medicine ,urogenital candidiasis ,fluconazole ,medicine ,Recurrent disease ,030212 general & internal medicine ,business.industry ,candidal vaginitis ,General Medicine ,Dermatology ,Candidal vaginitis ,Vulvovaginal Candidiasis ,vulvovaginal candidiasis ,Medicine ,business ,rvvc ,Vaginal infections ,Fluconazole ,medicine.drug - Abstract
Vulvovaginal candidiasis (VVC) is one of the most common vaginal infections, representing 40% to 50% of all cases of infectious vulvovaginitis. Between 70-75% of sexually active women experience at least one episode of VVC in their lifetime, and 8-10% of adult women have recurrent VVC. The treatment of VVC remains as one of the most pressing challenges of gynecology. The share of recurrent disease event rates remains high, despite the modern medicines used to treat various forms of VVC.
- Published
- 2019
- Full Text
- View/download PDF